Editorially independent content, supported with advertising
11.25.20
The next generation of therapy for DME patients will require looking beyond the VEGF pathway. In the phase 2 BOULEVARD study, researchers are assessing the safety and efficacy of the angiopoietin-2 mediator faricimab (Roche/Genentech) for the treatment of DME. Could the angiopoietin pathway present a new option for patients? Karl Csaky, MD, PhD, sits down with NRR to review data from the study, which were shared at this year’s AAO Annual Meeting Late Breakers session. This editorially independent podcast is supported with advertising.
08.21.25
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human GradersJohn Kitchens, MD; Krishna Mukkamala, MD
06.12.25
Duke AVS Clips: PVR, DR, Imaging, and MTMJason Hsu, MD; Majda Hadziahmetovic, MD; Aleksandra Rachitskaya, MD; Gavin Tan, MD, PhD, FRCSed
06.09.25
Duke AVS Clips: Pediatrics, Anesthesia Trends, and AILejla Vajzovic, MD; Jason Fan, MD; Glen J. Jaffe, MD
06.05.25
Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDsAvni P. Finn, MD, MBA; Lejla Vajzovic, MD, MBA; David Zacks, MD, PhD; Dilraj S. Grewal, MD; Xi Chen, MD, PhD; Yuxi Zheng, MD; Durga Borkar, MD; and Yannek I. Leiderman, MD, PhD
05.29.25
ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation DataMarion Munk, MD, PhD; and Diana Do, MD
05.22.25
ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the PipelineDavid Miller, MD; and Robert Wang, MD
12.05.24
AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer'sAdrienne Scott, MD; and Dilraj Grewal, MD
11.14.24
AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GADurga S. Borkar, MD, MMCi; and Alex Melamud, MD
11.07.24
AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMDJeremiah Brown, MD, MS; and Eric Schneider, MD
10.31.24
AAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining ReimbursementRahul Khurana, MD; and Paul Hahn, MD, PhD
Show More